The IDH2 Knockout HeLa Cell Line is a CRISPR/Cas9-edited human cell line with targeted disruption of the mitochondrial isocitrate dehydrogenase 2 (IDH2) gene. This defined loss-of-function model allows investigation of IDH2-dependent metabolic processes within an immortalized cervical adenocarcinoma background, enabling dissection of its role in the tricarboxylic acid (TCA) cycle, NADPH production, and cellular redox homeostasis.
The parental HeLa cell line originates from a human cervical adenocarcinoma and is characterized by its HPV18-positive status, conferring immortalization through viral oncogene expression. As one of the most extensively utilized mammalian cell models in biomedical research, HeLa cells serve as a foundational platform for studying cancer cell biology, signal transduction, and drug responses. The epithelial origin of HeLa cells makes them particularly relevant for investigating metabolic adaptations in carcinomas, including those driven by mitochondrial enzyme dysregulation.
IDH2 functions as a homodimeric enzyme in the mitochondrial matrix, catalyzing the oxidative decarboxylation of isocitrate to ??-ketoglutarate (??-KG) with concomitant reduction of NADP+ to NADPH. This reaction is a key control point of the TCA cycle, directly linking carbon metabolism to reducing equivalent production. IDH2 is regulated by transcription factors such as NRF2 (NFE2L2), FOXO family members, PPAR??, and HIF-1??, which modulate its expression in response to oxidative stress and metabolic demands. Downstream, IDH2-generated ??-KG serves as a substrate for TCA cycle progression, while NADPH fuels antioxidant defenses and supports the activity of ??-KG-dependent dioxygenases, including TET2 and JMJD histone demethylases. Additionally, IDH2 interacts with citrate synthase and mitochondrial malate dehydrogenase (MDH2), highlighting its integration within the mitochondrial metabolic network.
In the HeLa cervical cancer context, IDH2 knockout creates a genetically defined system to interrogate the role of mitochondrial NADPH production in sustaining proliferation and maintaining redox homeostasis. Given the elevated oxidative stress characteristic of many cancers, this cell line is particularly valuable for assessing how loss of IDH2-dependent antioxidant capacity influences cell survival. Although IDH2 mutations are more commonly associated with acute myeloid leukemia and glioma, the HeLa knockout model offers a versatile platform for elucidating fundamental metabolic principles underlying malignancy, including the interplay between the TCA cycle, glutamine metabolism, and 2-hydroxyglutarate dynamics. IDH2 disruption thus perturbs mitochondrial metabolism and redox balance, potentially impairing proliferation under oxidative stress.
Researchers can employ this IDH2 knockout HeLa cell line in a broad range of functional studies, including TCA cycle analysis, NADP+/NADPH ratio and ROS measurements, and metabolic profiling via metabolomics or OCR. IDH2-targeted therapy validation is supported by drug sensitivity and clonogenic assays, with LC-MS-based ??-KG quantification serving as a direct readout. Molecular confirmation by Western blot and RT-qPCR, together with proliferation and colony formation assays, enables comprehensive phenotypic characterization. For additional technical specifications or to discuss tailored experimental approaches, please contact Ascent Research.
